Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 118 participants.
Also called NCT03207945
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 118 participants
- Registry
-
NCT03207945
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03207945. Randomized; quadruple masking; primary purpose treatment. Start 2018-04-30 (actual); primary completion 2025-08-24 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)
- Acronym
- EPIC-HIV
- Condition
- Dyslipidemias
- Condition
- Cardiovascular Diseases
- Condition
- HIV Infections
- Intervention (Drug)
- Alirocumab
- Intervention (Other)
- Placebo
- Lead sponsor
- University of California, San Francisco
- Collaborator
- Massachusetts General Hospital
Record details
- Record id
cardio:ct-nct03207945- Content hash
eba239ad34dcffe310eca4fe125c8fcdd1dce6887c334def79ac74a41710eff6